Shares in newly listed Anxo Pharmaceutical Co Ltd (瑩碩生技) yesterday made modest gains on the Emerging Stock Board of the Taipei Exchange as the drug developer makes headway in the Chinese market. The stock rose 0.6 percent to NT$45.
Anxo on Monday announced that it had signed an agreement with a Chinese company based in Shenzhen to commercialize a generic psychoactive drug.
The two firms would work together to bring the drug through the regulatory approval process in China, Anxo said, without revealing further details due to confidentiality terms.
The generic drug is a treatment for depression that has already been approved for sale in Taiwan, Anxo spokesperson Hank Chen (陳志賢) said by telephone.
The drug would be manufactured in Taiwan and distributed in China by the company’s Chinese partner, Chen added.
Although the depression treatment has already been approved by Taiwanese authorities and could be eligible for China’s fast track status as a generic drug, it would still have to complete a full set of clinical trials in China, Chen said.
It is still too early to give a time table for the approval process and the company would monitor China’s regulations for changes, he said.
Anxo said China does not have a drug that equals its depression drug, so the product is expected to command a high price there.
The drug would have an estimated market value of US$150 million, and sales in China alone could reach 350 million yuan (US$51.23 million), the company said.
The company aims to take advantage of a new set of rules for evaluating generic drugs that was implemented by the China Food and Drug Administration in 2015.
The rules have cleared up China’s once chaotic queue for approving new drugs as developers with lower-quality clinical studies have withdrawn their applications to facilitate efforts to push through better-prepared companies, who are able to meet US and European standards regarding research, development and manufacturing capabilities, industry analysts have said.
Anxo in early May announced that it had signed a partnership with another Chinese company that would allow it to out-license a drug known only as NXR-606 in China.
Founded in 2003, Anxo reported a pre-tax income of NT$53.41 million in the first four months of the year, with its bottom line bouncing back into the black. Earnings per share as of the end of April were NT$0.98.
Sales in the first half of the year rose 27.02 percent year-on-year to NT$437 million, company data showed.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last